Equity Overview
Price & Market Data
Price: $34.35
Daily Change: +$0.65 / 1.89%
Daily Range: $34.11 - $35.40
Market Cap: $3,905,626,112
Daily Volume: 54,167
Performance Metrics
1 Week: 12.63%
1 Month: 2.18%
3 Months: 4.85%
6 Months: 13.39%
1 Year: 58.36%
YTD: -4.21%
Company Details
Employees: 53
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.